Table 1.
Demographic, clinical data and laboratory characterization of the individuals enrolled for this study.
| HC | MCI | AD | PD | Group comparison | |
|---|---|---|---|---|---|
| Clinical data | |||||
| Number | 40 | 35 | 40 | 28 | |
| Age, years [median; IQR] | 75.00 [72.75–78.00] | 75.00 [71.00–79.00] | 79.00 [73.25–80.75] | 74.00 [67.25–80.00] | nsb |
| Gender (M:F) | 16:24 | 14:21 | 18:22 | 18:10 | nsc |
| MMSE score [median; IQR] | nd | 25.7 [24.00–27.08] | 20.0 [16.88–22.60] | 24.7* [22.58–25.86] | p < 0.0001b |
| Y&H score [median; IQR] | nd | nd | nd | 2.5 [2.0–3.0] | |
| Laboratory findings | |||||
| APOE Ɛ4 Ɛ4-/Ɛ4- (%) | 80.0 | 62.9 | 47.5 | 75.0 | p = 0.01c |
| Ɛ4-/Ɛ4+ | 15.0 | 34.3 | 45.0 | 21.4 | p = 0.01c |
| Ɛ4 + /Ɛ4+ | 5.0 | 2.9 | 7.5 | 3.6 | ns |
| APOE Ɛ4 carriersa, % | 20.0 | 37.1 | 52.5 | 24.00 | p = 0.0053c |
| miR-223–3p, fold expression [median; IQR] | 0.97 [0.59–1.72] | 0.31 [0.19–0.85] | 0.21 [0.09–0.59] | 29.30 [12.43–133.25] | p < 0.0001b |
| Caspase-1, pg/ml [mean ± SEM] | 77.20 [9.79] | 137.76 [16.32] | 102.37 [9.24] | 263.52 [20.17] | p < 0.0001b |
AD, Alzheimer’s disease; MCI, Mild Cognitive Impairment; HC, healthy control; MMSE, Mini Mental State Evaluation; APOE: Apolipoprotein E;
Demographic, clinical and laboratory data are expressed as median and interquartile ranges (IQR) or mean ± standard error of the mean (SEM) as appropriate; apresence of one or two APOƐ4 alleles; bKruskal- Wallis test; cChi-square test, AD vs HC. *assessed in a subgroup of 17 PD patients.